| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy
|
Ji, Fanpu
|
|
|
23 |
8 |
p. 962-963
|
artikel
|
| 2 |
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
|
Kelley, Robin Kate
|
|
|
23 |
8 |
p. 995-1008
|
artikel
|
| 3 |
Cancer research investment could boost UK economy
|
Gourd, Elizabeth
|
|
|
23 |
8 |
p. 989
|
artikel
|
| 4 |
Cancer survival rates in Scotland
|
Burki, Talha Khan
|
|
|
23 |
8 |
p. e372
|
artikel
|
| 5 |
Carcinogenicity of occupational exposure as a firefighter
|
Demers, Paul A
|
|
|
23 |
8 |
p. 985-986
|
artikel
|
| 6 |
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
|
Vergote, Ignace
|
|
|
23 |
8 |
p. e374-e384
|
artikel
|
| 7 |
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis
|
Athanasiou, Antonios
|
|
|
23 |
8 |
p. 1097-1108
|
artikel
|
| 8 |
Coordinated efforts to harmonise gynaecological cancer care
|
Costa, Márcia
|
|
|
23 |
8 |
p. 971-972
|
artikel
|
| 9 |
Correction to Lancet Oncol 2022; 23: 990
|
|
|
|
23 |
8 |
p. e370
|
artikel
|
| 10 |
Correction to Lancet Oncol 2022; 23: 950–60
|
|
|
|
23 |
8 |
p. e370
|
artikel
|
| 11 |
Correction to Lancet Oncol 2022; 23: 1097–108
|
|
|
|
23 |
8 |
p. e370
|
artikel
|
| 12 |
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
|
Pautier, Patricia
|
|
|
23 |
8 |
p. 1044-1054
|
artikel
|
| 13 |
Early evidence for cancer in Sudan: an advanced example of bone metastases from ancient Nubia (circa 2500–2050 BCE)
|
Whiting, Rebecca
|
|
|
23 |
8 |
p. 992-994
|
artikel
|
| 14 |
ESMO World Congress on Gastrointestinal Cancer 2022
|
Gourd, Katherine
|
|
|
23 |
8 |
p. 988
|
artikel
|
| 15 |
Extreme weather, natural disasters, and cancer care
|
Burki, Talha Khan
|
|
|
23 |
8 |
p. 990
|
artikel
|
| 16 |
ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer
|
Milella, Michele
|
|
|
23 |
8 |
p. 991-992
|
artikel
|
| 17 |
Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study
|
Carroll, Robert P
|
|
|
23 |
8 |
p. 1078-1086
|
artikel
|
| 18 |
Importance of clinical research for the UK's 10-year cancer plan
|
Lee, Richard W
|
|
|
23 |
8 |
p. 975-978
|
artikel
|
| 19 |
Initiative to boost cancer care in the Philippines
|
Das, Manjulika
|
|
|
23 |
8 |
p. 984
|
artikel
|
| 20 |
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
|
Sehgal, Alison
|
|
|
23 |
8 |
p. 1066-1077
|
artikel
|
| 21 |
Managing immune checkpoint inhibition in transplant recipients
|
Lebbé, Céleste
|
|
|
23 |
8 |
p. 969-971
|
artikel
|
| 22 |
Members of parliament debate assisted dying in response to a petition calling for a change in the law
|
Wilkinson, Emma
|
|
|
23 |
8 |
p. e371
|
artikel
|
| 23 |
Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma
|
Buske, Christian
|
|
|
23 |
8 |
p. 967-969
|
artikel
|
| 24 |
MRI in the prognostic evaluation of patients with rectal cancer
|
Gao, Qingkun
|
|
|
23 |
8 |
p. e366
|
artikel
|
| 25 |
MRI in the prognostic evaluation of patients with rectal cancer – Authors' reply
|
Brown, Gina
|
|
|
23 |
8 |
p. e367
|
artikel
|
| 26 |
New legislation to promote paediatric studies for new cancer medicines
|
Hwang, Thomas J
|
|
|
23 |
8 |
p. e368-e369
|
artikel
|
| 27 |
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial
|
Reiss, Kim A
|
|
|
23 |
8 |
p. 1009-1020
|
artikel
|
| 28 |
Optical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial
|
Adan, Fieke
|
|
|
23 |
8 |
p. 1087-1096
|
artikel
|
| 29 |
Overturning Roe vs Wade undermines US cancer care
|
Gourd, Elizabeth
|
|
|
23 |
8 |
p. 987
|
artikel
|
| 30 |
Pancreatic cancer: still a cold case?
|
Reni, Michele
|
|
|
23 |
8 |
p. 964-965
|
artikel
|
| 31 |
Peru faces shortage of cancer drugs
|
Das, Manjulika
|
|
|
23 |
8 |
p. e373
|
artikel
|
| 32 |
PI3K inhibitors in haematological malignancies
|
Brown, Jennifer R
|
|
|
23 |
8 |
p. e364
|
artikel
|
| 33 |
PI3K inhibitors in haematological malignancies
|
Matasar, Matthew J
|
|
|
23 |
8 |
p. e365
|
artikel
|
| 34 |
PI3K inhibitors in haematological malignancies
|
Benjamin, David J
|
|
|
23 |
8 |
p. e362-e363
|
artikel
|
| 35 |
Problems with catch-up HPV vaccination after resumption of proactive recommendations
|
Sekine, Masayuki
|
|
|
23 |
8 |
p. 972-973
|
artikel
|
| 36 |
Progress on tobacco control and e-cigarettes
|
The Lancet Oncology,
|
|
|
23 |
8 |
p. 961
|
artikel
|
| 37 |
Project Orbis: the UK experience after 1 year
|
Lythgoe, Mark P
|
|
|
23 |
8 |
p. 978-981
|
artikel
|
| 38 |
Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
|
Lindsay, Holly B
|
|
|
23 |
8 |
p. e393-e401
|
artikel
|
| 39 |
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?
|
Moryoussef, Michael
|
|
|
23 |
8 |
p. e402
|
artikel
|
| 40 |
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
|
Budde, Lihua E
|
|
|
23 |
8 |
p. 1055-1065
|
artikel
|
| 41 |
Surrogate endpoints in breast cancer screening trials
|
Jatoi, Ismail
|
|
|
23 |
8 |
p. e360
|
artikel
|
| 42 |
Surrogate endpoints in breast cancer screening trials – Authors' reply
|
Heindel, Walter
|
|
|
23 |
8 |
p. e361
|
artikel
|
| 43 |
Systemic anti-cancer therapy treatment centres in Scotland at crisis point
|
Burki, Talha
|
|
|
23 |
8 |
p. 982-983
|
artikel
|
| 44 |
Terminology for cone dimensions after local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer: 2022 consensus recommendations from ESGO, EFC, IFCPC, and ESP
|
Kyrgiou, Maria
|
|
|
23 |
8 |
p. e385-e392
|
artikel
|
| 45 |
The impact of the EU General Data Protection Regulation on childhood cancer research in Europe
|
Vassal, Gilles
|
|
|
23 |
8 |
p. 974-975
|
artikel
|
| 46 |
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
|
Pagel, John M
|
|
|
23 |
8 |
p. 1021-1030
|
artikel
|
| 47 |
Zanubrutinib joins the CLL treatment buffet
|
Mozas, Pablo
|
|
|
23 |
8 |
p. 965-967
|
artikel
|
| 48 |
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
|
Tam, Constantine S
|
|
|
23 |
8 |
p. 1031-1043
|
artikel
|
Tijdschrift beschrijving